U.S. banking giant JPMorgan purchased 1.57 million Hong Kong-listed shares of WuXi AppTec for HK$75.33 million on Feb. 8.

FAST NEWS: JPMorgan boosts WuXi AppTec stake

The latest: U.S. banking giant JPMorgan purchased 1.57 million Hong Kong-listed shares of WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) for HK$75.33 million ($9.66 million) on Feb. 8, raising its stake in the drug…
Imminent US targeting casts shadow over future of WuXi AppTec

Potential U.S. targeting casts shadow over WuXi AppTec family

Proposed U.S. legislation could ban federal agencies and federally funded institutions from buying devices and services from Chinese biotech companies Key Takeaways: WuXi AppTec, which could be banned from doing…
Contract drug services provider WuXi Biologics announced on Wednesday it has raised its guidance for new projects in 2024 from 80 to 110, despite a slowdown in biotech financing, after seeing a strong recovery in demand in the second half of last year.

FAST NEWS: WuXi Biologics boosts new projects target

The latest: Contract drug services provider WuXi Biologics (Cayman) Inc. (2269.HK) announced on Wednesday it has raised its guidance for new projects in 2024 from 80 to 110, despite a…